Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-01-2015 | Uterine cancer | Book chapter | Article

1. Epidemiology of Endometrial Cancers and Uterine Sarcomas

Authors: Gauravi Mishra, MD, Sharmila Pimple, Surendra Shastri

Publisher: Springer India

Login to get access

Abstract

Globally, cancer of the body of the uterus, also known as corpus uteri cancer, is the sixth most common cancer among women. It has been estimated that in the year 2012, cancers of the corpus uteri accounted for 319,605 new cases. This accounted for 4.8 % of the total cancers among women with an age-standardized rate (ASR) of 8.3 per 100,000 women. There were an estimated 76,160 deaths due to endometrial cancers among women globally during 2012.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012. v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://​globocan.​iarc.​fr. Accessed 23 Dec 2014.
2.
American Cancer Society: Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013. Available online. Last accessed 14 May 2013.
3.
American Cancer Society Information. http://​www.​cancer.​org/​cancer/​endometrialcance​r/​detailedguide/​. Accessed 7 Jun 2015.
4.
Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. Br J Hosp Med. 1997;59:1055–60.
5.
Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lannom L, Hoover RN. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case–control study. Am J Obstet Gynecol. 1992;167:1317–25.CrossRefPubMed
6.
Reis N, Beji NK. Risk factors for endometrial cancer in Turkish women: results from a hospital-based case–control study. Eur J Oncol Nurs. 2009;13(2):122–7.CrossRefPubMed
7.
Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A, Chabbert-Buffet N, Boeing H, Schütze M, Trichopoulou A, Trichopoulos D, Lagiou P, Palli D, Krogh V, Tumino R, Vineis P, Mattiello A, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PH, Dumeaux V, Redondo ML, Duell E, Sanchez-Cantalejo E, Arriola L, Chirlaque MD, Ardanaz E, Manjer J, Borgquist S, Lukanova A, Lundin E, Khaw KT, Wareham N, Key T, Chajes V, Rinaldi S, Slimani N, Mouw T, Gallo V, Riboli E. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127(2):442–51.PubMed
8.
Pettersson B, Adami HO, Bergstrom R, Johansson ED. Menstruation span as a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynaecol Scand. 1986;65:247–55.CrossRef
9.
Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10:43–9.CrossRefPubMed
10.
Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol. 1991;164:522–7.CrossRefPubMed
11.
Kvåle G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res. 1988;48(21):6217–21.PubMed
12.
Jafari K, Javaheri G, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol. 1978;51:97–100.PubMed
13.
Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk (CASH-study). Gynecol Oncol. 2006;103:535–40.CrossRefPubMed
14.
Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10(4):277–84.CrossRefPubMed
15.
Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2002;105(2):166–9.CrossRefPubMed
16.
Beining RM, Dennis LK, Smith EM, Dokras A. Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol. 2008;18:492–9.CrossRefPubMed
17.
Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782–5.CrossRefPubMed
18.
Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, Brinton LA. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer. 2013;132(2):417–26.PubMedCentralCrossRefPubMed
19.
Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner’s guide to meta-analysis. Hum Reprod. 1997;12:1851–63.CrossRefPubMed
20.
Strom BL, Schinnar R, Weber AL, Bunin G, Berlin JA, Baumgarten M, DeMichele A, Rubin SC, Berlin M, Troxel AB, Rebbeck TR. Case–control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol. 2006;164(8):775–86.CrossRefPubMed
21.
Swerdlow AJ, Jones ME. British tamoxifen second cancer study group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case–control study. J Natl Cancer Inst. 2005;97(5):375–84.CrossRefPubMed
22.
Lavie O, Barnett-Griness O, Narod SA, Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer. 2008;18(2):352–6.CrossRefPubMed
23.
Lacey Jr JV, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010;28:788–92.PubMedCentralCrossRefPubMed
24.
Molina-Montes E, Pollán M, Payer T, Molina E, Dávila-Arias C, Sánchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol. 2013;130(2):340–5.CrossRefPubMed
25.
Chang SC, Lacey Jr JV, Brinton LA, Hartge P, Adams K, Mouw T, Carroll L, Hollenbeck A, Schatzkin A, Leitzmann MF. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2007;16(4):723–30.CrossRefPubMed
26.
Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jønsson L, Eriksen PS, Ottesen B. Risk factors among young women with endometrial cancer: a Danish case–control study. Am J Obstet Gynecol. 2000;182:23–9.CrossRefPubMed
27.
Tornberg SA, Carstensen JM. Relationship between Quetelet’s index and cancer of breast and female genital tract in 47 000 women followed for 25 years. Br J Cancer. 1994;69:358–61.PubMedCentralCrossRefPubMed
28.
McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, Gansler T, Thun MJ, Calle EE. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008;17(1):73–9.CrossRefPubMed
29.
Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Weight change and risk of endometrial cancer. Int J Epidemiol. 2006;35(1):151–8.CrossRefPubMed
30.
Rogers J, Mitchell GW. The relation of adiposity to menstrual disturbances. N Engl J Med. 1952;247:53–5.CrossRefPubMed
31.
Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205–12.PubMedCentralCrossRefPubMed
32.
Anderson DC. Sex hormone binding globulin. Clin Endocrinol. 1974;6:69–72.CrossRef
33.
Moore SC, Gierach GL, Schatzkin A, Matthews CE. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer. 2010;103(7):933–8.PubMedCentralCrossRefPubMed
34.
Levi F, Franceschi S, Negri E, La Vecchia C. Dietary factors and the risk of endometrial cancer. Cancer. 1993;71:3575–81.CrossRefPubMed
35.
Shu XO, Zheng W, Potischman N, Brinton LA, Hatch MC, Gao YT, Fraumeni Jr JF. A population-based case–control study of dietary factors and endometrial cancer in Shanghai, People’s Republic of China. Am J Epidemiol. 1993;137:155–65.PubMed
36.
Littman AJ, Beresford SA, White E. The association of dietary fat and plant foods with endometrial cancer (United States). Cancer Causes Control. 2001;12(8):691–702.CrossRefPubMed
37.
Maatela J, Aromaa A, Salmi T, Pohja M, Vuento M, Grönroos M. The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol Suppl. 1994;208:20–4.PubMed
38.
Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996;347:444–5.CrossRefPubMed
39.
Sun Y. Free radicals, antioxidant enzymes and carcinogenesis. Free Radic Biol Med. 1990;8:583–99.CrossRefPubMed
40.
Zhang ZH, Su PY, Hao JH, Sun YH. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer. 2013;23(2):294–303.CrossRefPubMed
41.
Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50:1365–74.CrossRefPubMed
42.
Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:276–80.CrossRefPubMed
43.
Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer. 1993;71:1702–9.CrossRefPubMed
44.
Kobayashi H, Uekuri C, Akasaka J, Ito F, Shigemitsu A, Koike N, Shigetomi H. The biology of uterine sarcomas: a review and update. Mol Clin Oncol. 2013;1:599–609.PubMedCentralPubMed
45.
Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Brinton LA. Evidence for a common etiology for endometrial carcinomas and malignant mixed Mullerian tumors. Gynecol Oncol. 1998;69:253–7.CrossRefPubMed
46.
Felix AS, Cook LS, Gaudet MM, Rohan TE, Schouten LJ, Setiawan VW, Wise LA, Anderson KE, Bernstein L, De Vivo I, Friedenreich CM, Gapstur SM, Goldbohm RA, Henderson B, Horn-Ross PL, Kolonel L, Lacey JV, Liang X, Lissowska J, Magliocco A, McCullough ML, Miller AB, Olson SH, Palmer JR, Park Y, Patel AV, Prescott J, Rastogi R, Robien K, Rosenberg L, Schairer C, Ou Shu X, van den Brandt PA, Virkus RA, Wentzensen N, Xiang YB, Xu WH, Yang HP, Brinton LA. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013;108(3):727–34.PubMedCentralCrossRefPubMed
47.
National Cancer Institute Information. http://​www.​ncbi.​nlm.​nih.​gov/​pubmedhealth/​PMHT0023668/​. Accessed 2 Dec 2013.
48.
Jaakkola S, Lyytinen HK, Pukkala E, Ylikorkala O. Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas. Gynecol Oncol. 2011;122(2):260–3.CrossRefPubMed
49.
Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive cancer centres’ ALERT group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 2000;356(9233):881–7.CrossRefPubMed
50.
Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94(2):256–66.CrossRefPubMed
51.
Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20(11):2758–60.PubMed